#USA #Burlington #PAQ Therapeutics #KRAS #PT0511

PAQ Therapeutics Achieves Key Milestones in Cancer Therapy Development

BURLINGTON, Mass., Jan. 22, 2026 – PAQ Therapeutics, an innovative clinical-stage oncology company focused on improving treatment for patients with KRAS-driven cancers, has announced significant advancements in its clinical programs. The company recently completed an extension of its Series B financing, raising the total to $77 million, and dosed its first patient in a Phase 1 clinical trial for PT0511, a groundbreaking pan-KRAS degrader.

Series B Extension: A Boost for Innovation

This financial boost was gathered through both existing and new investors, reflecting growing confidence in PAQ's potential to revolutionize cancer therapy. The additional funds will be strategically used to support the ongoing Phase 1 development of PT0253, PAQ's KRAS G12D degrader, alongside its promising candidates including PT0511.

Dr. Nan Ji, the CEO of PAQ Therapeutics, commented on these milestones, stating, "Completing this Series B extension and dosing the first patient in our PT0511 Phase 1 study represent significant achievements for us. These steps underscore our dedicated strategy to address the enormous unmet medical needs in treating KRAS-driven cancers."

PT0511: A New Hope in Cancer Treatment

PT0511 is engineered to target multiple oncogenic KRAS variants, marking a departure from traditional therapies restricted to single mutations. The Phase 1 clinical trial is designed as a first-in-human, open-label, dose-escalation study. Its main objectives include evaluating the safety and tolerability of PT0511 while also monitoring preliminary anti-tumor activity in patients with advanced solid tumors characterized by KRAS alterations.

Dr. Andrew Krivoshik, the Chief Medical Officer of PAQ, shared insights about the clinical development, emphasizing the broad potential of PT0511: "The initiation of clinical dosing with PT0511 expands our clinical portfolio and approaches cancer treatment through a pan-KRAS degradation strategy. This method aims to overcome challenges associated with current KRAS-targeted therapies, focusing on multi-mutation scenarios that are commonly encountered in patients."

Advancing the KRAS Pipeline

As an advocate of transformative solutions in biochemical therapies, PAQ Therapeutics aims to leverage targeted protein degradation to provide deeper and more selective suppression of oncogenic signaling. The company is committed to maintaining a favorable safety profile while enabling the potential for combination therapies that could enhance outcomes for patients facing KRAS-driven malignancies.

Conclusion

The developments announced by PAQ Therapeutics highlight a crucial moment in oncology, showcasing their commitment to pioneering new treatments for patients with limited options. As they embark on this Phase 1 trial, the medical community eagerly anticipates the impact that PT0511 and their other clinical candidates may have on patient care and outcomes in the fight against cancer.